Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of five randomized controlled trial(s). ^[1-5]
• Mean Diurnal Intraocular Pressure (IOP) Reductions: At Week 4, netarsudil 0.02% resulted in a mean diurnal IOP of 15.96 mmHg, significantly lower than 17.71 mmHg for ripasudil 0.4%, achieving a reduction of 1.74 mmHg (p < 0.0001). Netarsudil reduced mean diurnal IOP by 4.65 mmHg compared to a 2.98 mmHg reduction with ripasudil.
• Percentage Reductions from Baseline IOP: At Week 12, treatment-naive patients using netarsudil monotherapy experienced a 16.9% reduction, while patients switching from prostaglandin analogs saw a 2.5% reduction. In patients on concomitant therapy, netarsudil yielded a 20.5% reduction with one additional agent and 20.9% with two or more agents.
• Statistical Significance of IOP Reductions Compared to Placebo: In a study at Week 4, netarsudil concentrations of 0.01%, 0.02%, and 0.04% demonstrated mean diurnal IOP reductions of 4.10 mmHg (19.8%), 4.80 mmHg (23.5%), and 4.81 mmHg (23.8%), respectively, compared to 1.73 mmHg (8.2%) for placebo, all showing statistical significance.
• Adverse Events (AEs): Netarsudil exhibited a lower incidence of AEs (59.8%) compared to ripasudil (66.7%). The most common AE was conjunctival hyperemia, occurring in 54.9% of netarsudil patients versus 62.6% for ripasudil.
• Discontinuation Due to AEs: Discontinuation due to AEs was observed in 41 out of 260 (15.8%) netarsudil-treated patients, with 29 (11.2%) discontinuations attributed to AEs.
• Population Types and Subgroup Findings: Netarsudil 0.02% was significantly more effective than ripasudil 0.4% in Japanese patients, and its effectiveness was consistent across various real-world subgroups, including treatment-naive patients and those using netarsudil as concomitant therapy, with a reported 20.5% reduction for one additional agent and 20.9% for two or more agents.